Literature DB >> 24867962

Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.

Usha Stiefel1, Michelle M Nerandzic2, Michael J Pultz2, Curtis J Donskey3.   

Abstract

Antibiotics that are excreted into the intestinal tract may disrupt the indigenous intestinal microbiota and promote colonization by health care-associated pathogens. β-Lactam, or penicillin-type, antibiotics are among the most widely utilized antibiotics worldwide and may also adversely affect the microbiota. Many bacteria are capable, however, of producing β-lactamase enzymes that inactivate β-lactam antibiotics. We hypothesized that prior establishment of intestinal colonization with a β-lactamase-producing anaerobe might prevent these adverse effects of β-lactam antibiotics, by inactivating the portion of antibiotic that is excreted into the intestinal tract. Here, mice with a previously abolished microbiota received either oral normal saline or an oral cephalosporinase-producing strain of Bacteroides thetaiotaomicron for 3 days. Mice then received 3 days of subcutaneous ceftriaxone, followed by either oral administration of vancomycin-resistant Enterococcus (VRE) or sacrifice and assessment of in vitro growth of epidemic and nonepidemic strains of Clostridium difficile in murine cecal contents. Stool concentrations of VRE and ceftriaxone were measured, cecal levels of C. difficile 24 h after incubation were quantified, and denaturing gradient gel electrophoresis (DGGE) of microbial 16S rRNA genes was performed to evaluate the antibiotic effect on the microbiota. The results demonstrated that establishment of prior colonization with a β-lactamase-producing intestinal anaerobe inactivated intraintestinal ceftriaxone during treatment with this antibiotic, allowed recovery of the normal microbiota despite systemic ceftriaxone, and prevented overgrowth with VRE and epidemic and nonepidemic strains of C. difficile in mice. These findings describe a novel probiotic strategy to potentially prevent pathogen colonization in hospitalized patients.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867962      PMCID: PMC4136008          DOI: 10.1128/AAC.02782-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Impact of infection by vancomycin-resistant Enterococcus on survival and resource utilization for patients with leukemia.

Authors:  Peter B Bach; Sharp F Malak; Joseph Jurcic; Sarah E Gelfand; Janet Eagan; Claudia Little; Kent A Sepkowitz
Journal:  Infect Control Hosp Epidemiol       Date:  2002-08       Impact factor: 3.254

2.  A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

Authors:  S M Bhavnani; J A Drake; A Forrest; J A Deinhart; R N Jones; D J Biedenbach; C H Ballow
Journal:  Diagn Microbiol Infect Dis       Date:  2000-03       Impact factor: 2.803

3.  Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting.

Authors:  M A Montecalvo; W R Jarvis; J Uman; D K Shay; C Petrullo; H W Horowitz; G P Wormser
Journal:  Infect Control Hosp Epidemiol       Date:  2001-07       Impact factor: 3.254

Review 4.  Effect of antimicrobial agents on the ecological balance of human microflora.

Authors:  A Sullivan; C Edlund; C E Nord
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

5.  Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.

Authors:  John J Engemann; Yehuda Carmeli; Sara E Cosgrove; Vance G Fowler; Melissa Z Bronstein; Sharon L Trivette; Jane P Briggs; Daniel J Sexton; Keith S Kaye
Journal:  Clin Infect Dis       Date:  2003-02-07       Impact factor: 9.079

6.  Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  Anita Bhalla; Nicole J Pultz; Amy J Ray; Claudia K Hoyen; Elizabeth C Eckstein; Curtis J Donskey
Journal:  Infect Control Hosp Epidemiol       Date:  2003-09       Impact factor: 3.254

7.  Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes.

Authors:  Robert K Pelz; Pamela A Lipsett; Sandra M Swoboda; Marie Diener-West; Neil R Powe; Roy G Brower; Trish M Perl; Janet M Hammond; Craig W Hendrix
Journal:  Intensive Care Med       Date:  2002-04-12       Impact factor: 17.440

8.  Colonization and infection with multiple nosocomial pathogens among patients colonized with vancomycin-resistant Enterococcus.

Authors:  Curtis J Donskey; Amy J Ray; Claudia K Hoyen; Peter D Fuldauer; David C Aron; Ann Salvator; Robert A Bonomo
Journal:  Infect Control Hosp Epidemiol       Date:  2003-04       Impact factor: 3.254

9.  Coexistence of vancomycin-resistant enterococci and Staphylococcus aureus in the intestinal tracts of hospitalized patients.

Authors:  Amy J Ray; Nicole J Pultz; Anita Bhalla; David C Aron; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2003-09-12       Impact factor: 9.079

10.  Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial.

Authors:  Lennie P G Derde; Ben S Cooper; Herman Goossens; Surbhi Malhotra-Kumar; Rob J L Willems; Marek Gniadkowski; Waleria Hryniewicz; Joanna Empel; Mirjam J D Dautzenberg; Djillali Annane; Irene Aragão; Annie Chalfine; Uga Dumpis; Francisco Esteves; Helen Giamarellou; Igor Muzlovic; Giuseppe Nardi; George L Petrikkos; Viktorija Tomic; Antonio Torres Martí; Pascal Stammet; Christian Brun-Buisson; Marc J M Bonten
Journal:  Lancet Infect Dis       Date:  2013-10-23       Impact factor: 25.071

View more
  14 in total

1.  Metallo-β-lactamase-producing bacteroides species can shield other members of the gut microbiota from antibiotics.

Authors:  Usha Stiefel; Mary Ann Tima; Michelle M Nerandzic
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

2.  Enterococci and Their Interactions with the Intestinal Microbiome.

Authors:  Krista Dubin; Eric G Pamer
Journal:  Microbiol Spectr       Date:  2014-11

Review 3.  The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance.

Authors:  Melinda M Pettigrew; J Kristie Johnson; Anthony D Harris
Journal:  Ann Epidemiol       Date:  2016-03-08       Impact factor: 3.797

Review 4.  Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant Enterococcus in the Health Care Setting.

Authors:  Matthew L Faron; Nathan A Ledeboer; Blake W Buchan
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

5.  Antibiotic Degradation by Commensal Microbes Shields Pathogens.

Authors:  Mergim Gjonbalaj; James W Keith; Mytrang H Do; Tobias M Hohl; Eric G Pamer; Simone Becattini
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

Review 6.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01

7.  Lactobacillus paracasei CNCM I-3689 reduces vancomycin-resistant Enterococcus persistence and promotes Bacteroidetes resilience in the gut following antibiotic challenge.

Authors:  Laureen Crouzet; Muriel Derrien; Claire Cherbuy; Sandra Plancade; Mélanie Foulon; Benjamin Chalin; Johan E T van Hylckama Vlieg; Gianfranco Grompone; Lionel Rigottier-Gois; Pascale Serror
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

8.  Treatment with Saccharomyces boulardii and Escherichia coli Nissle is safe and associated with reduced nosocomial transmission of vanB vancomycin-resistant Enterococcus faecium on an early rehabilitation ward in Germany: a retrospective analysis.

Authors:  Stefan Borgmann; Beate Rieß; Rabea Siegmund; Guido Werner; Ingo Klare
Journal:  Ther Clin Risk Manag       Date:  2019-02-27       Impact factor: 2.423

9.  Characterization of aminoglycoside resistance and virulence genes among Enterococcus spp. isolated from a hospital in China.

Authors:  Wanxiang Li; Jing Li; Quhao Wei; Qingfeng Hu; Xiaowei Lin; Mengquan Chen; Renji Ye; Huoyang Lv
Journal:  Int J Environ Res Public Health       Date:  2015-03-11       Impact factor: 3.390

Review 10.  Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.

Authors:  Simon D Baines; Mark H Wilcox
Journal:  Antibiotics (Basel)       Date:  2015-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.